57 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
13 May 24
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
8:18am
securities are expected to fund operations into 2027.
Research and development expenses were $27.0 million for the three months ended March 31, 2024 … , compared to $25.5 million for the three months ended March 31, 2023. The increase in research and development expenses of $1.5 million was primarily
8-K
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Other Events
4:30pm
, continue its research and development activities in ulixacaltamide, PRAX-562 and PRAX-222 and for working capital and other general corporate purposes
424B5
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Prospectus supplement for primary offering
4:29pm
to accelerate the clinical development of PRAX-628, continue our research and development activities in ulixacaltamide, PRAX-562 and PRAX-222 and for working … research institution collaborators to continue research and development activities relating to our product candidates;
our ability to commercialize our
424B5
opz92
27 Mar 24
Prospectus supplement for primary offering
4:49pm
S-3
xkjyzujxuyh 0lm8uqp
5 Mar 24
Shelf registration
9:08am
8-K
EX-99.1
vyowuwde2q6fl29du
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
424B5
88cfl
12 Jan 24
Prospectus supplement for primary offering
5:20pm
424B5
17zfnx 2b
10 Jan 24
Prospectus supplement for primary offering
5:28pm
424B5
pxj jcobx1fw
7 Dec 23
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
olvqlh4rnz 51
7 Nov 23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7:35am
8-K
EX-99.1
xhwc4p fm27io7f
9 Aug 23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8:27am
424B5
06fkf4hxi62o
20 Jun 23
Prospectus supplement for primary offering
6:02am
424B5
s9o15ez xmd
15 Jun 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
2bigv3
11 May 23
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
7:31am